Thekey differencebetween baricitinib tofacitinib and upadacitinib is thatbaricitinib is aninhibitor的Jak1和Jak2while tofacitinib is an inhibitor of Jak1 andJak3和upadacitinib is a selective inhibitor of Jak1.
Janus kinase or JAK is a family of cytoplasmic non-receptor tyrosine kinase proteins. They are associated with cytokine receptors and activate members of signal transducer and activator of transcription (STAT) family of transcription factors. There are Janus kinase inhibitors. Tofacitinib, baricitinib, and upadacitinib are the three types of novel selective oral Janus activated kinase inhibitors inrheumatoid arthritis(RA)。
RA is a chronic systemic autoimmune disease characterized by persistent joint damage and extra-articular manifestations affecting many other organ systems. Cytokines are critical drivers of inflammation in RA. JAKs mediate downstream signaling of multiple cytokines and growth factors involved inflammatory and autoimmune disorders. Jak inhibitors are approved for the treatment of RA. Jak inhibitors selectively inhibit jak isoforms which are jak1, jak2, jak3 and tyk2. Tofacitinib inhibits Jak1 and Jak3 while baricitinib inhibits Jak1 and Jak2. Upadacitinib selectively inhibits Jak1.
内容
1.Overview and Key Difference
2.What is Baricitinib
3.What is Tofacitinib
4.What is Upadacitinib
5.Similarities Between Baricitinib Tofacitinib and Upadacitinib
6。Side by Side Comparison – Baricitinib vs Tofacitinib vs Upadacitinib in Tabular Form
7。概括
What is Baricitinib?
Baricitinib (brand nameolumiant)是成人类风湿关节炎(RA)的药物。它充当Janus激酶(JAK)的抑制剂,阻止了Jak1和Jak2子类型。这种药物会干扰免疫系统内导致RA症状的炎症过程。Bariticinib是60多个国家的成年人中适度活跃的RA的批准药物。Bariticinib作为平板电脑。

图01:Bariticinib
Long term treatment with baricitinib is effective in treating RA. Before starting the treatments for RA using baricitinib, it is very important to confirm whether you have previously been exposed to tuberculosis (TB) or hepatitis. Before starting baricitinib, it is necessary to undergo a course of treatment for latent (asymptomatic) TB. When considering hepatitis, baricitinib may increase the risk of the reactivation of hepatitis.
What is Tofacitinib?
tofacitinib(品牌名称Xeljanz)是另一种用于治疗类风湿关节炎(RA),银屑病关节炎和溃疡性结肠炎的JAK抑制剂。它也用于治疗特定的肠病(溃疡性结肠炎)。它有助于减少溃疡性结肠炎的症状,例如腹泻,直肠出血和胃痛。这是一个抑制JAK同工型1(JAK1)和3(JAK3)的小分子。

Figure 02: Tofacitinib
Basically, tofacitinib interferes with the JAK-STAT signaling pathway by blocking the body’s production of enzymes. Tofacitinib is available as tablets. It is taken orally. Similar to baricitinib, tofacitinib is a long-term treatment.
What is Upadacitinib?
upadacitinib(品牌rinvoq)是类似于Bariticinib和Tofacitinib的JAK抑制剂。这是一种第二代药物,通过阻断导致炎症的酶的作用选择性抑制JAK1。因此,它用于治疗成人中度至严重的活性类风湿关节炎。它也可以与甲氨蝶呤结合使用。与巴甲基尼和tofacitinib相比,upadacitinib具有亚型的选择性。

Figure 03: Upadacitinib
Upadacitib可以引起多种副作用,包括上呼吸道感染,例如普通感冒和窦感染等,恶心,咳嗽和发烧。除了这些常见的副作用外,Upadacitib还会引起严重的副作用,包括肺炎,蜂窝织炎和结核病。
有什么相似之处Baricitinib Tofa吗citinib and Upadacitinib?
- 巴甲替尼,tofacitib和upadacitib是Janus激酶(JAK)抑制剂药物或药物的类型。
- The three are approved drugs.
- Both significantly improve RA control.
- 他们被口服。
baritodinib tofacitinib和upadacitinib有什么区别?
Bariticinib是一种JAK抑制剂,抑制JAK同工型1和2,而Tofacitinib是第一代JAK抑制剂,抑制了亚型JAK1和JAK3。Upadacitib是第二代Janus激酶抑制剂,对JAK1具有选择性。因此,这是baritodinib tofacitinib和upadacitinib之间的关键区别。Olumiant是Bariticinib的品牌名称,而Xeljanz和Rinvoq分别是Tofacitinib和Upadacitinib的品牌名称。
下面的信息图表并排列甲替替尼和upadacitinib并排更多差异。
摘要 - bariticinib vs tofacitinib vs upadacitinib
Baricitinib, tofacitinib and upadacitinib are oral Jak inhibitors. They are approved drugs used to treat adults with moderately to severely active rheumatoid arthritis. Baricitinib inhibits Jak1 and 2 while tofacitinib inhibits Jak1 and 3. Upadacitinib selectively inhibits Jak1. Their brand names are Olumiant, Xeljanz and Rinvoq, respectively. Thus, this summarizes the difference between baricitinib tofacitinib and upadacitinib.
Reference:
1. “Baricitinib.” Versus Arthritis,Available here.
2. O’Shea, John J, et al. “Janus Kinase Inhibitors in Autoimmune Diseases.” Annals of the Rheumatic Diseases, U.S. National Library of Medicine, Apr. 2013,Available here.
Image Courtesy:
1. Ben Mills的“ Bariticinib-Portrait-ligand-3jw-from-pdb-xtal-xtal-xtal-4w9x-mercury-3d-balls” - Ben Mills - 自己的作品(公共领域)通过Commons Wikimedia
2. “Tofacitinib” By Vaccinationist – Own work, based on PubChem (Public Domain) viaCommons Wikimedia
3. “Upadacitinib” By jmorris0x0 – Own work(CC BY-SA 4.0)viaCommons Wikimedia
发表评论